Literature DB >> 28201843

Regression of Liver Fibrosis.

Lara Campana1, John P Iredale2.   

Abstract

Liver fibrosis is the final common pathway of chronic or iterative liver damage. Advanced chronic fibrosis is described as cirrhosis with a loss of architecture and attendant functional failure and the development of life-threatening complications. However, compelling evidence from rodent models and human studies indicates that if the injury is removed liver fibrosis is reversible. Hepatocytes, activated hepatic stellate cells, endothelial and immune cells, particularly macrophages, cooperate in the establishment and resolution of liver fibrosis. Here the authors provide a short overview of the mechanisms regulating the profibrotic and proresolution response, with the aim of highlighting potential new therapeutic targets. Liver disease is a major unmet medical need; currently, the sole approaches are the withdrawal of the injurious stimulus and liver transplantation. The authors conclude with a brief review of the feasibility of macrophage-based cell therapy for liver fibrosis. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28201843     DOI: 10.1055/s-0036-1597816

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  102 in total

1.  Clinical and Pathological Risk Factors Associated with Liver Fibrosis and Steatosis in African-Americans with Chronic Hepatitis C.

Authors:  Ali Afsari; Edward Lee; Babak Shokrani; Tina Boortalary; Zaki A Sherif; Mehdi Nouraie; Adeyinka O Laiyemo; Kawtar Alkhalloufi; Hassan Brim; Hassan Ashktorab
Journal:  Dig Dis Sci       Date:  2017-06-13       Impact factor: 3.199

2.  Myofibroblast Functions in Tissue Repair and Fibrosis: An Introduction.

Authors:  Victor J Thannickal
Journal:  Methods Mol Biol       Date:  2021

Review 3.  MR elastography of liver: current status and future perspectives.

Authors:  Ilkay S Idilman; Jiahui Li; Meng Yin; Sudhakar K Venkatesh
Journal:  Abdom Radiol (NY)       Date:  2020-07-23

Review 4.  siRNA- and miRNA-based therapeutics for liver fibrosis.

Authors:  Zhen Zhao; Chien-Yu Lin; Kun Cheng
Journal:  Transl Res       Date:  2019-08-13       Impact factor: 7.012

5.  Human placental mesenchymal stem cells ameliorate liver fibrosis in mice by upregulation of Caveolin1 in hepatic stellate cells.

Authors:  Yunqi Yao; Zhemin Xia; Fuyi Cheng; Qingyuan Jang; Jiao He; Cheng Pan; Lin Zhang; Yixin Ye; Yuan Wang; Shuang Chen; Dongsheng Su; Xiaolan Su; Lin Cheng; Gang Shi; Lei Dai; Hongxin Deng
Journal:  Stem Cell Res Ther       Date:  2021-05-20       Impact factor: 6.832

6.  Decreased expression of hsa_circ_0003570 in hepatocellular carcinoma and its clinical significance.

Authors:  Liyun Fu; Shengdong Wu; Ting Yao; Qingqing Chen; Yi Xie; Sheng Ying; Zhigang Chen; Bingxiu Xiao; Yaoren Hu
Journal:  J Clin Lab Anal       Date:  2017-05-11       Impact factor: 2.352

Review 7.  Advances in Magnetic Resonance Elastography of Liver.

Authors:  Jiahui Li; Sudhakar Kundapur Venkatesh; Meng Yin
Journal:  Magn Reson Imaging Clin N Am       Date:  2020-06-06       Impact factor: 2.266

Review 8.  Imaging of Hepatic Fibrosis.

Authors:  Rishi Philip Mathew; Sudhakar Kundapur Venkatesh
Journal:  Curr Gastroenterol Rep       Date:  2018-08-29

9.  Diagnosis of liver fibrosis in patients with hepatitis B-related liver disease using ultrasound with wave-number domain attenuation coefficient.

Authors:  Danqing He; Chaoxue Zhang; Wenqian Qiu; Qinxiu Xie
Journal:  Turk J Gastroenterol       Date:  2020-12       Impact factor: 1.852

10.  LRP6-CRISPR prevents activation of hepatic stellate cells and liver fibrogenesis in rats.

Authors:  Linghua Yu; Linlin Wang; Huixing Yi; Xiaojun Wu
Journal:  Am J Transl Res       Date:  2020-02-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.